Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience
{{output}}
Background: Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer is the most common type of advanced breast cancer. The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET... ...
